Barclays PLC Purchases 112,614 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX)

Barclays PLC grew its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 195.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 170,245 shares of the company’s stock after buying an additional 112,614 shares during the quarter. Barclays PLC’s holdings in Compass Therapeutics were worth $314,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Rovin Capital UT ADV bought a new position in Compass Therapeutics during the 3rd quarter valued at approximately $25,000. Intech Investment Management LLC purchased a new position in shares of Compass Therapeutics during the third quarter valued at approximately $30,000. XTX Topco Ltd bought a new position in shares of Compass Therapeutics during the third quarter valued at approximately $37,000. Cubist Systematic Strategies LLC purchased a new stake in Compass Therapeutics in the second quarter worth $41,000. Finally, SG Americas Securities LLC boosted its holdings in Compass Therapeutics by 16.6% in the third quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after acquiring an additional 5,515 shares in the last quarter. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Stock Up 11.4 %

Compass Therapeutics stock opened at $1.56 on Friday. Compass Therapeutics, Inc. has a twelve month low of $0.77 and a twelve month high of $2.34. The company has a market capitalization of $214.64 million, a P/E ratio of -4.22 and a beta of 0.89. The stock’s 50 day moving average is $1.57 and its 200 day moving average is $1.43.

Compass Therapeutics (NASDAQ:CMPX) last released its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. As a group, equities analysts expect that Compass Therapeutics, Inc. will post -0.35 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on CMPX shares. LADENBURG THALM/SH SH raised shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Monday, September 16th. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Monday, November 11th. Leerink Partners cut Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $5.00 to $4.00 in a research note on Friday, November 15th. Finally, D. Boral Capital started coverage on Compass Therapeutics in a report on Monday, December 23rd. They issued a “buy” rating and a $32.00 price objective for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.80.

Compass Therapeutics Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.